Samsung Biologics has announced an all-cash public tender offer to acquire PolyPeptide Group AG, valuing the peptide-focused contract development and manufacturing organization at approximately CHF 1.46 billion.
Under the terms of the planned offer, Samsung Biologics will seek 100% of PolyPeptide’s fully diluted share capital (excluding treasury shares) at CHF 44.31 per share. The price represents a 40% premium to PolyPeptide’s undisturbed share price of CHF 31.65 on April 10, 2026, and about an 11.6% premium to the volume-weighted average price over the prior 60 trading days. The transaction is expected to close toward the end of 2026, subject to a minimum acceptance level of two-thirds of shares, regulatory approvals, and other customary conditions.
PolyPeptide’s board, acting through its independent, non‑conflicted members, has unanimously recommended that shareholders accept the offer, calling it an attractive outcome and supportive of the company’s next phase of growth within Samsung Biologics’ global platform. PolyPeptide’s largest shareholder, holding roughly 55.65% of outstanding shares (excluding treasury shares), has agreed to tender its stake.
The deal would extend Samsung Biologics’ capabilities beyond antibodies and antibody-drug conjugates into peptide therapeutics, including GLP‑1–based drugs for obesity and diabetes, and peptide programs in oncology and other areas. PolyPeptide operates sites in Sweden, Belgium, France, the United States, and India, plus a corporate office in Switzerland and an innovation center in Strasbourg, providing development and commercial manufacturing of peptide active pharmaceutical ingredients.
Samsung Biologics said the acquisition is part of a broader multi‑modality growth strategy, expanding its service portfolio and geographic reach by integrating PolyPeptide’s peptide expertise and global operations into its CDMO network.